Radiotheranostics (RT) is one of the emerging divisions of nuclear medicine, usually implying positron emission tomography and radiotherapy. The same radionuclides can be used to perform the both tasks, or the imaging agent can have the same mechanism of uptake as the therapeutic agent, therefore the efficiency of treatment increases, while drug toxicity can be reduced. RT demonstrates rapid development within the last few years, including the novel radioisotope-labelled agents, nanosized magnetic and non-magnetic carriers and radiosensitizers, their preclinical trials and clinical use. Mostly used in oncology, RT is also used in neurology, gastroenterology and other branches of medicine. Further development of RT depends on both technological improvement in RT agents’ synthesis and on creation and implementation of the newer diagnostic and therapeutic equipment designed for RT.
The aim of the current Research Topic is to attract specialists in medical, physical and technical sciences, whose research draws on radiotheranostics. Moreover, we believe that systematic study in the field is possible only when basic, translational and clinical research groups are collaborating, therefore the results of this fruitful collaboration are welcome to be submitted. Since RT principles are still in continuous development, theoretical studies together with the recent experimental advances can give cumulative effect expressing in overcoming the present drawbacks of the conventional radiotherapy, which include inability to achieve the required radiation exposure in the field of pathological lesion due to unavoidable toxicity for the whole organism.
Areas to be covered in this Research Topic may include, but are not limited to:
- Development of radioisotope-labelled agents based on synthetic and biogenic components;
- Novel radioisotope and combined imaging techniques;
- Magnetic and non-magnetic nanosized radiosensitizers;
- Clinical trials and clinical efficacy of novel radioisotope-labelled agents;
- Recent advances in RT medical equipment;
- Comparative studies involving RT and other nuclear medicine techniques;
- RT for non-malignant disorders.
Radiotheranostics (RT) is one of the emerging divisions of nuclear medicine, usually implying positron emission tomography and radiotherapy. The same radionuclides can be used to perform the both tasks, or the imaging agent can have the same mechanism of uptake as the therapeutic agent, therefore the efficiency of treatment increases, while drug toxicity can be reduced. RT demonstrates rapid development within the last few years, including the novel radioisotope-labelled agents, nanosized magnetic and non-magnetic carriers and radiosensitizers, their preclinical trials and clinical use. Mostly used in oncology, RT is also used in neurology, gastroenterology and other branches of medicine. Further development of RT depends on both technological improvement in RT agents’ synthesis and on creation and implementation of the newer diagnostic and therapeutic equipment designed for RT.
The aim of the current Research Topic is to attract specialists in medical, physical and technical sciences, whose research draws on radiotheranostics. Moreover, we believe that systematic study in the field is possible only when basic, translational and clinical research groups are collaborating, therefore the results of this fruitful collaboration are welcome to be submitted. Since RT principles are still in continuous development, theoretical studies together with the recent experimental advances can give cumulative effect expressing in overcoming the present drawbacks of the conventional radiotherapy, which include inability to achieve the required radiation exposure in the field of pathological lesion due to unavoidable toxicity for the whole organism.
Areas to be covered in this Research Topic may include, but are not limited to:
- Development of radioisotope-labelled agents based on synthetic and biogenic components;
- Novel radioisotope and combined imaging techniques;
- Magnetic and non-magnetic nanosized radiosensitizers;
- Clinical trials and clinical efficacy of novel radioisotope-labelled agents;
- Recent advances in RT medical equipment;
- Comparative studies involving RT and other nuclear medicine techniques;
- RT for non-malignant disorders.
